Multiple sclerosis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 3: | Line 3: | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Cost | ==Cost effectiveness== | ||
Given the [[morbidity]] and [[mortality]] associated with multiple sclerosis and the high cost of treating the acute attacks and [[disability]] of [[MS]] disease, treatment with [[Interferon beta-1a|IFN β-1a]] [[Subcutaneous|SC]] injection, [[Interferon beta-1b|IFNβ-1b]] [[Subcutaneous|SC injection]], and [[glatiramer acetate]] is relatively [[Cost-effectiveness|cost-effective]]. | |||
==References== | ==References== | ||
Revision as of 16:16, 4 March 2018
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis cost-effectiveness of therapy |
|
Multiple sclerosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Multiple sclerosis cost-effectiveness of therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Cost effectiveness
Given the morbidity and mortality associated with multiple sclerosis and the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective.